PTM Biolabs, a Chinese firm that develops proteomics technology to help diagnose and treat human diseases, has raised 530 million yuan ($80 million) in a Series B round of financing led by Beijing-based investment firm IDG Capital, per its announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
